The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients
Open accessAbstract
Purpose: A new generation of molecularly targeted agents is entering the definitive stage of clinical evaluation. Many of these drugs benefit only a subset of treated patients and may be overlooked by the traditional, broad-eligibility approach to randomized clinical trials. Thus, there is a need for development of novel statistical methodology for rapid evaluation of these agents. Experimental Design: We propose a new adaptive design for randomized clinical trials of targeted agents in settings where an assay or signature that identifies sensitive patients is not available at the outset of the study. The design combines prospective development of a gene expression–based classifier to select sensitive patients with a properly powered test for overall effect. Results: Performance of the adaptive design, relative to the more traditional design, is evaluated in a simulation study. It is shown that when the proportion of patients sensitive to the new drug is low, the adaptive design substantially reduces the chance of false rejection of effective new treatments. When the new treatment is broadly effective, the adaptive design has power to detect the overall effect similar to the traditional design. Formulas are provided to determine the situations in which the new design is advantageous. Conclusion: Development of a gene expression–based classifier to identify the subset of sensitive patients can be prospectively incorporated into a randomized phase III design without compromising the ability to detect an overall effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (1996) · Machine Learning · doi:10.1007/bf00058655 · Cited by 16,325
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationShipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
Grunwald, V., & Hidalgo, M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.851 · Cited by 383
Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials
Simon, R., & Maitournam, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0496 · Cited by 325
Self-citationTargeting epidermal growth factor receptor—are we missing the mark?
Dancey, J. E., & Freidlin, B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13810-x · Cited by 192
Self-citationEnd points in cancer clinical trials and the drug approval process.
Schilsky, R. L. (2002) · PubMed · Cited by 170
Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical Trials
Betensky, R. A., Louis, D. N., & Gregory Cairncross, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.140 · Cited by 167
Improving the evaluation of new cancer treatments: challenges and opportunities
Rothenberg, M. L., Carbone, D. P., & Johnson, D. H. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1047 · Cited by 145
Evaluation of Randomized Discontinuation Design
Freidlin, B., & Simon, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.520 · Cited by 92
Self-citation
Cited by
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Simon, R. M., Paik, S., & Hayes, D. F. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp335 · Cited by 1,037
Self-citationVansteenkiste, J. F., Cho, B. C., Vanakesa, T., De Pas, T., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00099-1 · Cited by 511
Tutorial in biostatistics: data‐driven subgroup identification and analysis in clinical trials
Lipkovich, I., Dmitrienko, A., & B., R. (2017) · Statistics in Medicine · doi:10.1002/sim.7064 · Cited by 291
Lipkovich, I., Dmitrienko, A., Denne, J., & Enas, G. (2011) · Statistics in Medicine · doi:10.1002/sim.4289 · Cited by 281
A 2020 vision for vaccines against HIV, tuberculosis and malaria
Rappuoli, R., & Aderem, A. (2011) · Nature · doi:10.1038/nature10124 · Cited by 273
Metadata
- Authors
- Freidlin, B., & Simon, R.
- Venue
- Clinical Cancer Research
- Published
- 2005-11-01
- Volume
- 11
- Issue
- 21
- Pages
- 7872-7878
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2114850871
- Cited by
- 349
- References
- 13
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-0605
- The paper
- Freidlin, B., & Simon, R. (2005). Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-0605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.